Most Read Articles
01 Apr 2013
Aspergillus colonization may lead to an increase in the risk of bronchiolitis obliterans syndrome. This study determined the impact of colonization of conidia Aspergillus species after post lung transplantation.
16 Jan 2018
No standard currently exists for the growing number of patients with multidrug-resistant strains of Helicobacter pylori, but a recent study has shown the safety and reliability of a 12-day low-dose rifabutin/high-dose proton pump inhibitor (PPI) regimen in patients infected with triple-resistant strains.
Roshini Claire Anthony, 10 Jan 2018

Adding rifampicin to standard antibiotic therapy does not improve outcomes in individuals with Staphylococcus aureus (S. aureus) bacteraemia, the ARREST* trial shows. However, rifampicin may contribute towards a minor reduction in bacteraemia recurrence.

14 Jan 2018
Patients with a first episode of Clostridium difficile infection (CDI) are likely to respond to treatment with fidaxomicin with no recurrences, a recent study has shown. On the other hand, those with prior CDI episodes are less likely to respond, especially with >1 prior episode, and more likely to recur, which suggests a greater clinical benefit of fidaxomicin earlier in the course of CDI.

PPI use ups gastric cancer risk in H. pylori-infected patients

12 Nov 2017

In patients infected with Helicobacter pylori, long-term use of proton pump inhibitors (PPIs) is associated with an increased risk of gastric cancer (GC) even after treatment for the infection, a recent population-based study has shown.

The research team retrieved clinical information of 63,397 adults (median age at treatment 54.7 years; 46.5 percent male) who had taken at least 7 days of clarithromycin-based triple therapy for H. pylori infection. Those who failed the regimen or had been diagnosed with GC within 12 months of treatment for H. pylori were excluded.

Cox proportional hazards models were used to determine the risk of GC associated with PPI use. Propensity score adjustments were performed to control for differences in background factors.

In the cohort, 0.24 percent (n=153) developed gastric cancer following treatment for H. pylori. Of these cancers, 20.3 percent (n=31) were in the cardia and 62.1 percent (n=95) were in noncardia regions. Sites were unspecified for the remaining 17.6 percent (n=27) of the cases.

Following propensity score adjustment without trimming, PPI users were significantly at a higher risk of gastric cancer (hazard ratio [HR], 2.44; 95 percent CI, 1.42 to 4.20; p=0.002) compared with nonusers. The significant association remained after trimming (HR, 2.14; 1.27 to 3.58; p=0.004).

Multivariable analysis reflected the same elevated risk of GC after H. pylori therapy, with an HR value of 2.19 (1.31 to 3.66; p=0.003).

The difference in absolute risk of gastric cancer between patients who took PPIs and those who did not was 4.29 per 10,000 person-years after propensity score adjustments.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Apr 2013
Aspergillus colonization may lead to an increase in the risk of bronchiolitis obliterans syndrome. This study determined the impact of colonization of conidia Aspergillus species after post lung transplantation.
16 Jan 2018
No standard currently exists for the growing number of patients with multidrug-resistant strains of Helicobacter pylori, but a recent study has shown the safety and reliability of a 12-day low-dose rifabutin/high-dose proton pump inhibitor (PPI) regimen in patients infected with triple-resistant strains.
Roshini Claire Anthony, 10 Jan 2018

Adding rifampicin to standard antibiotic therapy does not improve outcomes in individuals with Staphylococcus aureus (S. aureus) bacteraemia, the ARREST* trial shows. However, rifampicin may contribute towards a minor reduction in bacteraemia recurrence.

14 Jan 2018
Patients with a first episode of Clostridium difficile infection (CDI) are likely to respond to treatment with fidaxomicin with no recurrences, a recent study has shown. On the other hand, those with prior CDI episodes are less likely to respond, especially with >1 prior episode, and more likely to recur, which suggests a greater clinical benefit of fidaxomicin earlier in the course of CDI.